Table 1.

Characteristics of the included studies.

NCT	NCT01984242 (25)	NCT02420821 (26)	NCT02684006 (27)	NCT02811861 (28)	NCT02853331 (29)	NCT03141177 (30)
Study	Immotion150	Immotion151	Javelin Renal 101	—	Keynote-426	CheckMate 9ER
Year	2018	2019	2020	2021	2019	2021
Author	McDermott, D. F.	Rini, B. I.	Motzer, R. J.	Motzer, R. J.	Rini, B. I.	Choueiri, T. K.
Treatment arms	Atezolizumab+ Bevacizumab*	Atezolizumab+ Bevacizumab	Avelumab+ Axitinib	Pembrolizumab+ Levatinib**	Pembrolizumab+ Axitinib	Nivolumab+ Cabozantinib***
Control	Sunitinib	Sunitinib	Sunitinib	Sunitinib	Sunitinib	Sunitinib
Number of patients	101 vs. 101	454 vs. 461	442 vs. 444	355 vs. 357	432 vs. 429	323 vs. 328
Median age(years)	62 vs. 61	62 vs. 60	62 vs. 61	64 vs. 62	62 vs. 61	62 vs. 61
Sex (male% / female%)	73/27 vs. 78/22	70/30 vs. 76/24	71/29 vs. 77/23	72/28 vs. 77/23	71/29 vs. 75/25	77/23 vs. 71/29
PD-L1 +(% of patients)	50 vs. 59	49 vs. 40	55 vs. 25	30 vs. 33	59 vs. 62	26 vs. 25
Prognostic model	MSKCC	MSKCC	IMDC	IMDC**** and MSKCC	IMDC	IMDC
Favorable risk %	30 vs. 21	20 vs. 20	21 vs. 22	31 vs. 35	32 vs. 30	23 vs. 22
Intermediate risk %	61 vs. 69	69 vs. 69	61 vs. 62	59 vs. 54	55 vs. 57	58 vs. 57
Poor risk %	9 vs. 10	11 vs. 11	16 vs. 16	9 vs. 10	13 vs. 12	19 vs. 21
Primary endpoints	PFS	OS, PFS	OS, PFS	OS, PFS	OS, PFS	OS, PFS
Median PFS (months)	11.7 vs. 8.4	11.2 vs. 8.4	13.8 vs. 8.4	23.9 vs. 9.2	15.1 vs. 11.1	16.6 vs. 8.3
Median OS (months)	NR	33.6 vs. 34.9	NR	NR	NR	NR
ORR	NR	151/454 vs. 144/460	227/442 vs. 114/444	252/355 vs. 129/357	256/432 vs. 153/429	180/323 vs. 89/328

NR not reported, PFS progression-free survival, OS overall survival, ORR objective response ratio.

* Atezolizumab alone arm was not considered.

**Levatinib and Everolimus combination arm was not considered.

***Nivolumab, Ipilimumab and Cabozantinib combination arm was not considered.

****Only IMDC was adopted in our analysis